Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study

BACKGROUND AND PURPOSE: Fixed-dose combinations of a long-acting beta agonist and an inhaled corticosteroid are more effective than the individual components in COPD. The primary study objective was to demonstrate that the combination indacaterol acetate/mometasone furoate (IND/MF [QMF149]) was non-...

Descripción completa

Detalles Bibliográficos
Autores principales: Beeh, Kai Michael, Kirsten, Anne-Marie, Tanase, Ana-Maria, Richard, Alexia, Cao, Weihua, Hederer, Bettina, Beier, Jutta, Kornmann, Oliver, van Zyl-Smit, Richard N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287650/
https://www.ncbi.nlm.nih.gov/pubmed/30584293
http://dx.doi.org/10.2147/COPD.S179293

Ejemplares similares

Ejemplares similares